Table 1 Therapeutic efficacy data of therapeutic and control group mice bearing CT-26 tumor.

From: Dual blockage of both PD-L1 and CD47 enhances the therapeutic effect of oxaliplatin and FOLFOX in CT-26 mice tumor model

Groups (n = 5 for each group)

TTEa (days) ± SD

TGDb (%)

ILSc (%)

Control

21.54 ± 3.46

–

–

OXP

22.25 ± 0.63

3.3

13.5

FOLFOX

25 ± 2.28

16.06

18.4

OXP + anti-CD47

27.49 ± 3.81

27.61

30

OXP + anti-PDL-1

26.81 ± 3.7

24.44

25.2

OXP + anti-CD47 + anti-PDL-1

35.62 ± 8.43

65.34

63.1

FOLFOX + anti-CD47 + anti-PDL-1

44.83 ± 8.21

108.06

98

  1. aTime to reach end point.
  2. bTumor growth delay.
  3. cIncrease Life Span.
Back to article page